PAYAL KUMAR: Open Payments
NPI 1588271068 · SCARSDALE, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,361 in 51 payments from 15 companies in 2025. Trend: 2023 $2,087 · 2024 $2,369 · 2025 $1,361
Food & beverage: $1,266Education: $95
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 9 | $260 |
| Astellas Pharma US Inc | 5 | $215 |
| AstraZeneca Pharmaceuticals LP | 7 | $177 |
| Esperion Therapeutics, Inc. | 8 | $176 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $166 |
| GlaxoSmithKline, LLC. | 4 | $104 |
| ABBVIE INC. | 2 | $51 |
| Lilly USA, LLC | 2 | $43 |
| Amgen Inc. | 2 | $38 |
| Exact Sciences Corporation | 2 | $38 |
Products named: Ozempic, NEXLETOL, CAPLYTA, Veozah, TRELEGY ELLIPTA, AIRSUPRA, FASENRA, Rybelsus.
Industry payments across NY — which companies pay providers there.
